These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22866946)

  • 1. Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.
    Rusconi S; Giacomet V; Mameli C; Viganò A; Viganò O; Adorni F; Galli M; Zuccotti GV
    BMC Infect Dis; 2012 Aug; 12():179. PubMed ID: 22866946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
    Ross LL; Weinberg WG; DeJesus E; Fischl MA; Horton JH; Pappa KA; Lancaster CT; Pakes GE; Smith KY
    AIDS Res Hum Retroviruses; 2010 Apr; 26(4):407-17. PubMed ID: 20380480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution-Based Antiretroviral Therapy.
    Ross LL; Cotton MF; Cassim H; Garges HP; van Dijkman SC; Morarji K; Karthika S; Danehower S; Radford J; Butcher D
    AIDS Res Hum Retroviruses; 2024 Oct; 40(10):606-613. PubMed ID: 38973446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
    Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
    Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
    Fortuny C; Duiculescu D; Cheng K; Garges HP; Cotton M; Tamarirt DP; Ford SL; Wire MB; Givens N; Ross LL; Lou Y; Perger T; Sievers J
    Pediatr Infect Dis J; 2014 Jan; 33(1):50-6. PubMed ID: 23811744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
    Collier AC; Tierney C; Downey GF; Eshleman SH; Kashuba A; Klingman K; Vergis EN; Pakes GE; Rooney JF; Rinehart A; Mellors JW;
    HIV Clin Trials; 2008; 9(2):91-102. PubMed ID: 18474494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
    Murphy RL; Berzins B; Zala C; Fichtenbaum C; Dube MP; Guaraldi G; Torriani F; Belsey E; Mitchell C; Stein JH;
    AIDS; 2010 Mar; 24(6):885-90. PubMed ID: 19952712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
    Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
    Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
    Blick G; Greiger-Zanlungo P; Gretz S; Han J; Dupree D; Garton T; Yau LH; Wine BC; Pakes GE;
    Int J STD AIDS; 2012 Mar; 23(3):e18-22. PubMed ID: 22581890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
    Aberg JA; Tebas P; Overton ET; Gupta SK; Sax PE; Landay A; Falcon R; Ryan R; De La Rosa G
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1184-95. PubMed ID: 22352336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects.
    Carosi ; Lazzarin ; Stellbrink ; Moyle ; Rugina ; Staszewski ; Givens ; Ross ; Granier ; Ait-Khaled ; Leather ; Nichols
    HIV Clin Trials; 2009; 10(6):356-67. PubMed ID: 20133266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
    Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
    HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up.
    Quercia R; Garnier E; Ferré V; Morineau P; Bonnet B; Soulard C; Raffi F
    HIV Clin Trials; 2005; 6(2):73-80. PubMed ID: 15983891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
    Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.